U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H5O3S2.Na
Molecular Weight 164.179
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MESNA

SMILES

[Na+].[O-]S(=O)(=O)CCS

InChI

InChIKey=XOGTZOOQQBDUSI-UHFFFAOYSA-M
InChI=1S/C2H6O3S2.Na/c3-7(4,5)2-1-6;/h6H,1-2H2,(H,3,4,5);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C2H5O3S2
Molecular Weight 141.189
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f http://www.drugbank.ca/drugs/DB09110 https://en.wikipedia.org/wiki/Mesna

Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL733: 4-Hydroxyifosfamide
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
MESNEX

Approved Use

Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1)

Launch Date

5.9944318E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33 μM
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
511 μM
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79 μM
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
110 μM × h
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
201 μM × h
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
49 μM × h
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
92 min
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (43.8%)
Hypoaesthesia (0%)
Malaise (0%)
Myalgia (0%)
Nausea (0%)
Pharyngitis (0%)
Somnolence (6.3%)
Upper respiratory infection (0%)
Vomiting (0%)
Dizziness (6.3%)
Abdominal pain (6.3%)
Coughing (0%)
Diarrhea (6.3%)
Anorexia (0%)
Flushing (12.5%)
Injection site reaction (12.5%)
Back pain (6.3%)
Dyspepsia (12.5%)
Paraesthesia (6.3%)
Renal pain (6.3%)
Rigors (12.5%)
Fatigue (0%)
Conjunctivitis (6.3%)
Arthralgia (12.5%)
Application site reaction (31.3%)
Photophobia (18.8%)
Dehydration (6.3%)
Dysuria (6.3%)
Sweating increased (6.3%)
Sources:
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (33.3%)
Hypoaesthesia (0%)
Malaise (8.3%)
Myalgia (0%)
Nausea (16.7%)
Pharyngitis (0%)
Somnolence (8.3%)
Upper respiratory infection (0%)
Vomiting (16.7%)
Dizziness (8.3%)
Abdominal pain (8.3%)
Coughing (0%)
Diarrhea (0%)
Anorexia (8.3%)
Flushing (0%)
Injection site reaction (0%)
Back pain (0%)
Dyspepsia (0%)
Paraesthesia (8.3%)
Renal pain (0%)
Rigors (0%)
Fatigue (8.3%)
Conjunctivitis (0%)
Arthralgia (0%)
Application site reaction (0%)
Photophobia (0%)
Dehydration (0%)
Dysuria (0%)
Sweating increased (0%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anorexia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Coughing 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Fatigue 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Hypoaesthesia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Malaise 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Myalgia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Nausea 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Pharyngitis 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Upper respiratory infection 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Vomiting 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Arthralgia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Dyspepsia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Flushing 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Injection site reaction 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Rigors 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Photophobia 18.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Application site reaction 31.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Headache 43.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Abdominal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Back pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Conjunctivitis 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Dehydration 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Diarrhea 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Dizziness 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Dysuria 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Paraesthesia 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Renal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Somnolence 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Sweating increased 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy
n = 16
Application site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Arthralgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Back pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Conjunctivitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Coughing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Dehydration 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Diarrhea 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Dyspepsia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Dysuria 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Flushing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Hypoaesthesia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Injection site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Myalgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Pharyngitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Photophobia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Renal pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Rigors 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Sweating increased 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Upper respiratory infection 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Nausea 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Vomiting 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Headache 33.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Abdominal pain 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Anorexia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Dizziness 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Fatigue 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Malaise 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Paraesthesia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
Somnolence 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy
n = 12
PubMed

PubMed

TitleDatePubMed
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
1980 Sep 27
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
1981
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
1982
Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
1983 Feb
Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
1983 Feb 15
Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna.
1983 Sep
Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukaemia.
1983 Sep
Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
1984 Dec
The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
1984 May
[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
1984 Sep
Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study.
1984 Sep
Ifosfamide, mesna, and encephalopathy.
1985 Jun 15
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
1985 May
Cause and prevention of mafosfamide-induced venous pain.
1986
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
1986
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
1986
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
1986 Aug
Avoiding ifosfamide/mesna encephalopathy.
1986 Aug 16
Prediction of ifosfamide/mesna associated encephalopathy.
1986 Jul
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
1986 Jun
Phase II study of ifosfamide in cervical cancer.
1986 Jun
Blurring of vision due to ifosfamide.
1987
Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.
1987
Ifosfamide/mesna encephalopathy.
1987 Apr 25
Irreversible encephalopathy with ifosfamide/mesna.
1987 Aug
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
1987 Aug
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
1987 Feb
Ifosfamide neurotoxicity in children.
1987 Mar
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
1987 May
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
1988
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
1988
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
1988 May
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
1989 Jul
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
1989 Jun
Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion.
1990
[Ifosfamide-induced urinary bladder lesion and its inhibition by mesna].
1990 Aug
Dana-Farber Cancer Institute studies in advanced sarcoma.
1990 Feb
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
1991
[Epileptic seizures and treatment with ifosfamide-mesna].
1994
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
1995 Jun
[The prevention of hemorrhagic cystitis during the performance of bone marrow and peripheral blood stem cell transplantation in the hematologic cancer clinic].
1996
Ifosfamide encephalopathy and methylene-blue: a case report.
1996 Aug
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
1996 Jun
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
1997
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
1997
A 50-year-old man with burkitt lymphoma.
2008 Oct
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
2008 Sep
Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis.
2011 Jan
Surface functionalities of gold nanoparticles impact embryonic gene expression responses.
2013 Mar
Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.
2014 Jan-Feb
Patents

Sample Use Guides

240 mg/m2 every 4 hours (injection) or 240 mg/m2 (first point, injection) following with 480 mg/m2 (2 and 6 hours, oral).
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Thu Jul 06 23:21:27 UTC 2023
Edited
by admin
on Thu Jul 06 23:21:27 UTC 2023
Record UNII
NR7O1405Q9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MESNA
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
MESNEX
Brand Name English
MESNA [MART.]
Common Name English
UROMITEXAN
Brand Name English
D 7093
Code English
MESNA [VANDF]
Common Name English
MESNA [USAN]
Common Name English
COENZYME M SODIUM SALT
Common Name English
D-7093
Code English
MESNA [USP IMPURITY]
Common Name English
SODIUM 2-MERCAPTOETHANE SULFONATE
Systematic Name English
MESNA [JAN]
Common Name English
SODIUM 2-MERCAPTOETHANESULPHONATE
Systematic Name English
Mesna [WHO-DD]
Common Name English
MESNA [EP MONOGRAPH]
Common Name English
mesna [INN]
Common Name English
MESNA [MI]
Common Name English
SODIUM 2-SULPHANYLETHANESULPHONATE
Systematic Name English
ETHANESULFONIC ACID, 2-MERCAPTO-, MONOSODIUM SALT
Common Name English
Sodium 2-mercaptoethanesulfonate
Systematic Name English
MESNA [ORANGE BOOK]
Common Name English
MESNA [USP MONOGRAPH]
Common Name English
NSC-113891
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 24887
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
NDF-RT N0000180854
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
NCI_THESAURUS C2082
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
LIVERTOX 606
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
WHO-VATC QR05CB05
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
WHO-VATC QV03AF01
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
WHO-ATC V03AF01
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
FDA ORPHAN DRUG 8685
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
WHO-ATC R05CB05
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID1020809
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
MERCK INDEX
M7249
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY Merck Index
RS_ITEM_NUM
1392807
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
NCI_THESAURUS
C192
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
ECHA (EC/EINECS)
243-285-9
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
INN
2813
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
MESH
D015080
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
CHEBI
17905
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
WIKIPEDIA
MESNA
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
PUBCHEM
23662354
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
ChEMBL
CHEMBL1098319
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
FDA UNII
NR7O1405Q9
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
EVMPD
SUB08784MIG
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
DRUG CENTRAL
1711
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
SMS_ID
100000092488
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
RXCUI
44
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY RxNorm
USAN
BB-59
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
DRUG BANK
DB09110
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
NSC
113891
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
CAS
19767-45-4
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
DAILYMED
NR7O1405Q9
Created by admin on Thu Jul 06 23:21:28 UTC 2023 , Edited by admin on Thu Jul 06 23:21:28 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 0.01
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 0.01
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 0.01
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC